IO Biotech, Inc. (IOBT)


-0.27 (-9.57%)
Symbol IOBT
Price $2.55
Beta 0.000
Volume Avg. 0.08M
Market Cap 73.479M
Shares () -
52 Week Range 2.15-9.77
1y Target Est -
DCF Unlevered IOBT DCF ->
DCF Levered IOBT LDCF ->
ROE -66.68% Strong Sell
ROA -75.18% Strong Sell
Operating Margin -
Debt / Equity 5.65% Neutral
P/E -
P/B 0.48 Neutral


Consensus EPS

Upgrades & Downgrades

NASDAQ Global Select

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.